Study of Minirin Melt® in Adult Patients With Nocturia

NCT03089073 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 835

Last updated 2021-02-05

No results posted yet for this study

Summary

Observation of safety and efficacy of Minirin Melt® in adult patients with nocturia

Conditions

  • Nocturia

Interventions

DRUG

Desmopressin

60μg or 120μg once daily at bedtime

Sponsors & Collaborators

  • Ferring Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Global Clinical Compliance · Ferring Pharmaceuticals

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-13
Primary Completion
2018-10-05
Completion
2018-10-05

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03089073 on ClinicalTrials.gov